Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has provided an announcement.
SSY Group Limited has received approval from China’s National Medical Products Administration for a new 1ml:1mg specification of its Cyanocobalamin (Vitamin B12) Injection, alongside confirmation that the product has passed the quality and efficacy consistency evaluation for generic drugs. This marks the second such approval for the group’s entities in China, strengthening its position in injectable treatments for conditions such as megaloblastic anemia and certain degenerative neurological diseases, and signalling continued progress in its product development pipeline.
The newly approved Cyanocobalamin Injection is indicated primarily for megaloblastic anemia caused by intrinsic factor deficiency and can also be used as an adjunct therapy for subacute combined degenerative neurological conditions such as neuritis. By expanding specifications and securing regulatory recognition of generic quality, SSY Group enhances its competitiveness in China’s regulated generics market and offers additional therapeutic options to clinicians and patients.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a pharmaceutical company focused on developing and manufacturing injectable drugs for the China market. The group’s product portfolio targets key therapeutic areas, supplying hospitals and healthcare institutions with generic formulations tailored to domestic clinical needs.
Average Trading Volume: 9,745,783
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.02B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.